尿激酶溶栓治疗高龄急性心肌梗死

Application of Urokinase Thrombolysis for Acute Myocardial Infarction in Advanced Age

目的 探讨尿激酶静脉溶栓治疗高龄急性心肌梗死的疗效及安全性。方法 选择高龄组 (>6 5岁 ) 1 2 0例 ,低龄组 (≤ 6 5岁 ) 1 36例 ,两组除给予冠心病AMI常规治疗药物外 ,均给予尿激酶静脉溶栓治疗。结果 高龄组与低龄组比较冠脉再通率 (5 3 3与 5 7 4 % ) ,4周内死亡率 (8 3%与 5 9% ) ,出血发生率 (6 7%与5 9% ) ,差异无显著性意义 (P >0 .0 5 )。结论 尿激酶静脉溶栓治疗高龄岁 (>6 5岁 )AMI是一种安全、有益且有效的治疗措施 ,不应把年龄列为溶栓禁忌 。

Objective To explore the effective and safety coefficient of urokinase venous thrombolysis to acute myocardial infarction in advanced age.Methods Select advanced age group 120 cases (>65 years old),low age group 136 cases(≤65 years old),besides an offer routine treatment to AMI coronary heart disease in two groups,all were given the urokinase venous thrombolysis treatment.Results Compare the coronary artery recanalization rate in advanced age group and low age group( 53.3 % and 57.4 %),death rate in 4 weeks( 8.3 % and 5.9 %),bleeding rate ( 6.7 % and 5.9 %).The difference does not have significance meaning(P> 0.05 ).Conclusion Urokinase venous thrombolysis to treat advanced age(>65 years old)AMI is a kind of safe,beneficial and effective treatment measure,should not classify age as thrombolysis taboo,should actively create chance for advanced age AMI patient.